BCTX BriaCell Therapeutics
- 2.230
- -0.020-0.87%
- 2.190
- -0.040-1.81%
BriaCell Therapeutics News
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting
BriaCell Therapeutics (BCT.TO), which is developing immunotherapies to treat cancer, said it will make a presentation on the clinical data of the randomized Phase 2 study evaluating Bria-IMT in patien
BriaCell Announces Oral and Poster Presentations at ASCO 2024
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell)
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+(TM) and Bria-PROS+(TM) Clinical Candidates for Breast and Prostate Cancer
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+ and Bria-PROS+ Clinical Candidates for Breast and Prostate Cancer
Preclinical data shows that BriaCell's Bria-OTS+ and Bria-PROS+ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, a
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR
BriaCell Therapeutics (BCT.TO), a clinical-stage biotechnology company, is presenting positive clinical data from its lead product candidate, Bria-IMT, in two of its three poster sessions during the 2
BriaCell Highlights Data For Antibody-Drug Conjugate Resistant And Central Nervous System Metastatic Breast Cancer At AACR 2024
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT pivotal Phase 3 formulation is twice that of controls in similar studiesPFS results reinforced by larger number of prior treatmen
Canada Net Change Percentage Gainers & Losers
GAINERS COMPANY SYMBOL LAST CHANGE PERCENT VOLUME ------- ------ ---- ------ ------- ------ Nevada Cop
BriaCell Receives And Executes Letter Of Intent To Advance Clinical Development Of Breast And Prostate Cancer Immunotherapies
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell's novel off-the-shelf personalized cancer va
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that
BriaCell Provides Update On Alleged Illegal Trading of Public Securities
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechno
BriaCell Reports Prelim Disease Control Rate Of 61% In Evaluable Phase 2 Advanced Breast Cancer Patients Treated With Briacell's Bria-imt Regimen; Control Rate Of 50% Reported In Evaluable Patients Who Failed Prior ADC Therapy
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal Phase 3 studyDisease control rate of 50% in evaluable patients treated with t
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
Bria-Pros+ is based on BriaCell's next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells and natural
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnol
Briacell Therapeutics Filed For Mixed Shelf Offering Of Up To $200M
Briacell Therapeutics Filed For Mixed Shelf Offering Of Up To $200M
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient With "Eye-Bulging" Metastatic Breast Cancer
HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $18 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 price target.
BriaCell Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/28/2023 230.28% HC Wainwright & Co. → $18 Reiterates Buy → Buy 10/03/2023 266.97% HC Wainwright & Co. $
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT, alone and in combination with an immune checkpoint
Analysis
Price Target
No Data
